Who
Eric Dobmeier
Director
Company insider
Files Form 4 as: Director, Structure Therapeutics; Director, Janux Therapeutics; Director, Jade Biosciences; Director, Atara Biotherapeutics; President, CEO, Chinook Therapeutics; Director, Adaptive Biotechnologies; Director, Versartis; Chief Operating Officer, Seattle Genetics Inc /wa.
In numbers
- Trades disclosed
- 641
- Buys
- 16
- Sells
- 63
- Bought
- $602K
- Sold
- $38.8M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 31 Jan 2006
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,804 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,667 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,017 at $0.00 | filing |
| 19 Jul 2024filed 24 Jul 2024 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,111 at $0.00 | filing |
| 19 Jul 2024filed 24 Jul 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,231 at $0.00 | filing |
| 19 Jul 2024filed 22 Jul 2024 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 19 Jul 2024filed 22 Jul 2024 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,350 at $0.00 | filing |
| 19 Jul 2024filed 22 Jul 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 19 Jul 2024filed 22 Jul 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 10 Nov 2023filed 14 Nov 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $103K446,825 at $0.23 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Company StockADPT · dailypolitical.com · 21 Oct 2026Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 6,444 Shares of StockADPT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Eric Dobmeier; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.